Tocilizumab in patients infected by SARS-CoV2.
作者信息
Sancho Milagros, Muñiz Javier, Cardinal-Fernández Pablo
机构信息
Unidad de Cuidados Intensivos, Hospital Universitario Gregorio Marañón, Madrid, España.
Departamento de Ciencias de la Salud, Universidad de A Coruña; Fundación de investigación HM Hospitales, Galicia.
出版信息
Med Clin (Barc). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcli.2020.12.003. Epub 2021 Jan 28.
Abstract
摘要
相似文献
1
Tocilizumab in patients infected by SARS-CoV2.托珠单抗用于感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者。
Med Clin (Barc). 2021 Apr 23;156(8):402-406. doi: 10.1016/j.medcli.2020.12.003. Epub 2021 Jan 28.
2
Tocilizumab: From Rheumatic Diseases to COVID-19.托珠单抗：从风湿性疾病到 COVID-19。
Curr Pharm Des. 2021;27(13):1597-1607. doi: 10.2174/1381612827666210311141512.
3
Trends of thrombo-inflammation biomarkers after Tocilizumab predict treatment failure better than scores in patients with severe SARS-CoV2 related respiratory failure.托珠单抗治疗后血栓炎症生物标志物的变化趋势比严重SARS-CoV2相关呼吸衰竭患者的评分更能预测治疗失败。
Eur J Intern Med. 2022 Sep;103:111-112. doi: 10.1016/j.ejim.2022.06.004. Epub 2022 Jun 6.
4
Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy.继发抗体缺陷患者中持续的 SARS-CoV-2 感染：使用 casirivimab 和 imdevimab（REGN-COV2）单克隆抗体联合治疗后成功清除。
Ann Clin Microbiol Antimicrob. 2021 Dec 30;20(1):85. doi: 10.1186/s12941-021-00491-2.
5
Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.托珠单抗治疗期间伴 MOG 抗体相关疾病的良性 SARS-CoV-2 感染。
Mult Scler Relat Disord. 2020 Nov;46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.
6
Duration of infectious viral shedding in patients with mild to moderate COVID-19 treated with REGN-CoV2.在接受 REGN-CoV2 治疗的轻度至中度 COVID-19 患者中，传染性病毒脱落的持续时间。
J Infect Chemother. 2022 Jul;28(7):912-917. doi: 10.1016/j.jiac.2022.03.013. Epub 2022 Mar 22.
7
Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease.托珠单抗治疗 COVID-19 患者：新型疾病推荐药物。
Int Immunopharmacol. 2020 Dec;89(Pt A):107018. doi: 10.1016/j.intimp.2020.107018. Epub 2020 Sep 16.
8
Impact of Timing of Tocilizumab Use in Hospitalized Patients With SARS-CoV-2 Infection.托珠单抗使用时机对住院的2019冠状病毒病感染患者的影响
Respir Care. 2022 May;67(5):629-630. doi: 10.4187/respcare.10067.
9
Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.测试托珠单抗对新冠肺炎肺炎患者的疗效。
J Comp Eff Res. 2021 Jun;10(8):625-627. doi: 10.2217/cer-2021-0050. Epub 2021 Apr 23.
10
Tocilizumab prescribing criteria for COVID-19 patients.COVID-19患者的托珠单抗处方标准。
Hum Vaccin Immunother. 2021 Apr 3;17(4):1128. doi: 10.1080/21645515.2020.1822137. Epub 2020 Oct 20.
引用本文的文献
1
Clinical characteristics and outcomes of 1,331 patients with COVID-19: HM Spanish Cohort.1331 例 COVID-19 患者的临床特征和结局：HM 西班牙队列。
Rev Esp Quimioter. 2021 Aug;34(4):342-352. doi: 10.37201/req/050.2021. Epub 2021 May 19.
本文引用的文献
1
Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial.在一项随机对照试验中，使用托珠单抗治疗的 2019 年冠状病毒病患者的预后和预测生物标志物。
Crit Care Med. 2022 Mar 1;50(3):398-409. doi: 10.1097/CCM.0000000000005229.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.托珠单抗对重症或危重症 2019 冠状病毒病患者 15 天临床结局的影响：随机对照试验。
BMJ. 2021 Jan 20;372:n84. doi: 10.1136/bmj.n84.
4
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19.托珠单抗治疗 COVID-19 住院患者的疗效。
N Engl J Med. 2020 Dec 10;383(24):2333-2344. doi: 10.1056/NEJMoa2028836. Epub 2020 Oct 21.
5
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
6
Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia: A Randomized Clinical Trial.托珠单抗与标准治疗对 COVID-19 肺炎住院患者临床恶化的影响：一项随机临床试验。
JAMA Intern Med. 2021 Jan 1;181(1):24-31. doi: 10.1001/jamainternmed.2020.6615.
7
COVACTA trial raises questions about tocilizumab's benefit in COVID-19.COVACTA试验引发了关于托珠单抗在新冠病毒肺炎中疗效的质疑。
Lancet Rheumatol. 2020 Oct;2(10):e592. doi: 10.1016/S2665-9913(20)30313-1. Epub 2020 Sep 9.
8
Crucial laboratory parameters in COVID-19 diagnosis and prognosis: An updated meta-analysis.新型冠状病毒肺炎诊断和预后的关键实验室参数：一项更新的荟萃分析。
Med Clin (Engl Ed). 2020 Aug 28;155(4):143-151. doi: 10.1016/j.medcle.2020.05.004. Epub 2020 Aug 22.
9
Efficacy of tocilizumab treatment in severely ill COVID-19 patients.托珠单抗治疗重症 COVID-19 患者的疗效。
Crit Care. 2020 Aug 27;24(1):524. doi: 10.1186/s13054-020-03224-7.
10
Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.重症监护病房中新冠肺炎患者使用托珠单抗的多中心观察性研究。
Lancet Rheumatol. 2020 Oct;2(10):e603-e612. doi: 10.1016/S2665-9913(20)30277-0. Epub 2020 Aug 14.
Zotero 插件